Phase II clinical study of Durvalumab (MEDI4736) plus Tremalimumab for the treatment of patients with advanced neuroendocrine tumors of gastroenteropathic or pulmonary origin (DUNE)
INDEPENDENT CLINICAL TRIAL
Clinical trial information
- Promoter: GETNE (SPANISH GROUP OF NEUROENDOCRINE AND ENDOCRINE TUMORS)
- Phase: II
- Execution start: 23/03/2017
- End of execution: 30/03/2019
- IP: ENCARNA GONZALEZ FLORES